TREK channels produce background currents that regulate cell excitability. These channels are sensitive to a wide variety of stimuli including polyunsaturated fatty acids (PUFAs), phospholipids, mechanical stretch, and intracellular acidification. They are inhibited by neurotransmitters, hormones, and pharmacological agents such as the antidepressant fluoxetine. TREK1 knockout mice have impaired PUFA-mediated neuroprotection to ischemia, reduced sensitivity to volatile anesthetics, altered perception of pain, and a depression-resistant phenotype. Here, we investigate TREK1 regulation by Gq-coupled receptors (GqPCR) and phospholipids. Several reports indicate that the C-terminal domain of TREK1 is a key regulatory domain. We developed a fluorescent-based technique that monitors the plasma membrane association of the C terminus of TREK1 in real time. Our fluorescence and functional experiments link the modulation of TREK1 channel function by internal pH, phospholipid, and GqPCRs to TREK1-C-terminal domain association to the plasma membrane, where increased association results in greater activity. In keeping with this relation, inhibition of TREK1 current by fluoxetine is found to be accompanied by dissociation of the C-terminal domain from the membrane.T REK1 is a two-pore-domain K + (K 2P ) channel that produces a nearly time-and voltage-independent background current. This current drives the membrane potential toward the K + equilibrium potential and thus affects input resistance. TREK1 displays low basal activity when expressed alone (1) but can be strongly stimulated by temperature (2), mechanical stretch (3), external alkalization (4), intracellular acidification (5), polyunsaturated fatty acids (PUFAs) (6), lysophospholipids (7), phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] (8, 9), and pharmacological agents such as volatile anesthetics (10) and riluzole (11). TREK1 is inhibited by neurotransmitters and hormones that activate Gq and Gs pathways (3,(12)(13)(14) and pharmacological agents such as the antidepressant drug fluoxetine (15). TREK1 gene inactivation produces mice with decreased sensitivity to volatile anesthetics, impaired PUFA-mediated neuroprotection (16), and altered perception of pain (17). These mice also display a depression-resistant phenotype (18). This phenotype is in agreement with the sensitivity of TREK1 to fluoxetine, a widely used antidepressant drug.In the last decade, much effort has been made to elucidate the gating mechanism of the TREK1 channel. The cytosolic carboxylterminal domain of TREK1 that follows its fourth transmembrane domain (post-M4) has been implicated in its function and regulation. A glutamate residue, E306, has been shown to be a key element for stimulation by intracellular acidification (19) and a cluster of basic residues in the same region has been shown to be involved in TREK1 regulation by phospholipid (8). However, the mechanism of regulation of the channel by Gq-coupled receptors (GqPCR) and by pharmacological agents such as fluoxetine remains unclear.I...